Acta Med. 2025, 68: 45-49
Prognostic Impact of Baseline Serum Creatinine in Patients with Advanced High-Grade Serous Ovarian Carcinoma Undergoing Neoadjuvant Chemotherapy
, Jiří Špaček, Jr.b, Munachiso Iheme Ndukwea, Denisa Pohankovác, Eva Čermákovác, Igor Sirákc, Jiří Špačeka
aDepartment of Obstetrics and Gynecology, Charles University, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Hradec Králové, Czech Republic
bDepartment of Urology, Charles University, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Hradec Králové, Czech Republic
cDepartment of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Hradec Králové, Czech Republic
Received July 14, 2025
Accepted August 15, 2025
Objective: To evaluate whether baseline serum creatinine is associated with survival outcomes in patients with advanced high-grade serous ovarian carcinoma undergoing neoadjuvant chemotherapy. Methods: We retrospectively analyzed 77 patients treated between 2009 and 2018. Patients were stratified by baseline serum creatinine levels (<84 vs. ≥84 µmol/L), and survival outcomes were assessed using Kaplan-Meier analysis. Results: No statistically significant differences in progression-free or overall survival were observed between groups. A trend toward shorter OS in the elevated creatinine group did not reach significance. Conclusion: Baseline serum creatinine was not found to be a statistically significant prognostic marker in this cohort. These results highlight the need for adjusted analyses incorporating established prognostic factors in future research.
Keywords
ovarian cancer, neoadjuvant chemotherapy, serum creatinine, prognosis.
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
